Latanoprost Azad

Latanoprost, the active ingredient in Latanoprost Azad, is a prostaglandin analog presented as an ophthalmic solution for ocular use. It lowers intraocular pressure and is used to treat primary open-angle glaucoma and ocular hypertension. GNH USA supplies Latanoprost Azad as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Latanoprost is a prostaglandin analog used to manage ocular pressure‑related conditions. - Primary open-angle glaucoma: reduces intraocular pressure to slow disease progression. - Ocular hypertension: lowers intraocular pressure to prevent development of glaucoma.

Latanoprost may cause a range of ocular and systemic reactions.

Common Side Effects: - Eye redness: mild conjunctival hyperemia. - Eye itching: transient pruritus. - Blurred vision: temporary visual disturbance. - Increased eyelash growth: longer, thicker lashes. - Darkening of iris: gradual pigmentation change. - Eye irritation: mild burning or stinging.

Serious or Rare Side Effects: - Severe eye inflammation: uveitis or iritis requiring medical attention. - Allergic reaction: swelling, rash, or hives. - Vision loss: sudden decrease in visual acuity. - Ocular pain: persistent discomfort. - Corneal edema: swelling of the cornea. - Periorbital fat atrophy: loss of tissue around the eye.

Before initiating therapy, consider the following safety measures. - Monitor intraocular pressure: assess response after starting treatment. - Assess for ocular infections: avoid use if active infection is present. - Caution in cystoid macular edema: discontinue if edema worsens. - Avoid contact lens wear during treatment: lenses may trap the drug. - Discontinue if severe reaction occurs: seek ophthalmologic evaluation. - Store at room temperature: keep in original container, protect from light and moisture.

Latanoprost may interact with other ocular or systemic agents.

Major Interactions (Avoid): - Concomitant use with other prostaglandin analogs: additive ocular effects and increased risk of inflammation. - Use with systemic carbonic anhydrase inhibitors: may potentiate intraocular pressure reduction leading to hypotony.

Moderate Interactions (Monitor Closely): - Combination with beta‑blocker eye drops: monitor for excessive pressure lowering. - Use with topical corticosteroids: increased risk of cataract formation. - Interaction with non‑steroidal anti‑inflammatory drugs (NSAIDs): may affect ocular surface tolerance.